"We have made significant strides in moving our GnRH program forward with three active Phase II clinical trials underway, a substantially complete preclinical package, as well as completing a commercial manufacturing and formulation process. To date we have treated approximately 500 subjects in our GnRH trials with elagolix. Elagolix has been generally safe and well tolerated with clinically meaningful reduction in endometriosis symptoms, such as dysmenorrhea, in most study participants. On the GnRH partnering front, we continue in collaboration discussions with multiple pharmaceutical companies. We will not speculate on a timeline for the completion of this deal," said Kevin Gorman, Ph.D., President and Chief Executive Officer of Neurocrine Biosciences. "Our goals for the GnRH program are to continue building value through our clinical trials and to secure the very best partner to fully develop this important asset. On the financial front, we continue to effectively manage our cash burn by prioritizing spending while advancing our pipeline."
R & D Pipeline Update
Neurocrine's clinical development group and corporate partners have five programs in clinical development and will report on R & D progress throughout 2008. Neurocrine scientists continue to supply Neurocrine's pipeline to meet the Company-wide goal of bringing one new compound into development each year.
GnRH Antagonists for endometriosis
Elagolix in Three Phase II Clinical Trials for Endometriosis
Below is a summary of the current ongoing randomized placebo controlled
Phase II trials for elagolix:
Trial Study Design Endpoints n Status Results
0603 Six-month treatment 1. I
|SOURCE Neurocrine Biosciences, Inc.|
Copyright©2008 PR Newswire.
All rights reserved